Skip to main content
OpenTrials
Completed

NCT Number: NCT05294666

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment

It is planned to explore the efficacy and safety of local 0.05% cyclosporine eye drops in the treatment of chronic graft-versus-host eye disease. Through the comparative study with 0.1% tacrolimus eye drops, to clarify the short-term and long-term efficacy of 0.05% CSA in these patients, and to explore the benefits of long-term maintenance of local cyclosporine to patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Graft Versus Host Disease in Eye Dry Eye Syndromes Eye Diseases Lacrimal Apparatus Diseases

Age range

4 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Peking University Third Hospital

Beijing, Beijing Municipality, 100000, China

About this study

Chronic graft-versus-host disease (GVHD) is a common and serious complication after allogeneic hematopoietic stem cell transplantation. Its clinical presentation is similar to that of an autoimmune disease and can affect many organs, including the skin, liver, gastrointestinal tract, lungs and eyes. Ocular GVHD occurs in 30-60% of patients undergoing hematopoietic stem cell transplantation and 60-90% of patients with other systemic GVHD. Chronic ocular GVHD usually occurs 9-24 months after hematopoietic stem cell transplantation and mainly affects the cornea, conjunctiva, lacrimal gland, eyelid and meibomian gland, and leads to inflammation and fibrosis of these tissues. The characteristic manifestations of chronic GVHD include dry keratoconjunctivitis, cicatric conjunctivitis, punctate keratopathy, corneal ulcer and perforation. Severe dry eye is the most common manifestation of ocular GVHD. Patients have burning sensation, foreign body sensation, photophobia, dry eye, itching and other symptoms. This is associated with reduced tear secretion due to damage to the lacrimal gland as well as with goblet cell loss and tear film instability due to meibomian gland dysfunction. Chronic eye GVHD has the potential to cause severe visual impairment and significantly reduce the patient's quality of life. The principle of topical treatment of ocular GVHD is to lubricate the ocular surface, reduce ocular surface inflammation, prevent tear evaporation, and promote epithelial repair. Specific local treatment options include glucocorticoids, immunosuppressants, growth factors and artificial tears. Local glucocorticoids are the first-line treatment at the present stage, but the side effects of hormone therapy are relatively large. Long-term use can lead to damaged epithelial formation, thinning of the cornea, increased intraocular pressure, cataract, infectious keratitis, etc. Therefore, it is necessary to closely monitor the treatment period and minimize the use time. At present, the most commonly used topical immunosuppressants are tacrolimus (FK506) and cyclosporine (CsA). Both belong to calcineurin inhibitors, which can inhibit the activation of calcium-dependent T cells, thus exerting immunosuppressive effect. 0.05% CsA is an eye drop mainly used for the treatment of moderate and severe dry eye, with good therapeutic effect and tolerability [18-23], but slow onset of effect. In the treatment of patients with chronic ocular GVHD, previous studies have shown that cyclosporine eye drops can improve patients' dry eye symptoms, reduce corneal fluorescence staining, and increase tear film rupture time. However, the number of clinical studies on the treatment of chronic ocular GVHD with 0.05% CsA eye drops is limited, with a small number of patients enrolled and relatively short follow-up time. The immunosuppressive effect of tacrolimus is significantly higher than cyclosporine, which is 100 times higher than reported in literature. Therefore, tacrolimus is mainly used for the treatment of rejection after corneal transplantation and immune-related ocular surface diseases. What is the efficacy and tolerability of such a powerful immunosuppressant in treating GVHD? There are few literature reports, but long-term ocular application can reduce local immunity and increase the risk of local infection. At the same time, tacrolimus is very irritating, and some patients cannot tolerate it and choose to stop using the drug. At present, there is still a lack of clinical evidence to compare the efficacy of cyclosporine and tacrolimus eye drops in patients with chronic ocular GVHD. Therefore, by comparing the effectiveness, safety and tolerance of 0.05% CsA eye drops and 0.1% tacrolimus eye drops in the treatment of chronic eye graft-versus host eye disease, this study aims to explore a reasonable treatment plan for chronic eye GVHD and provide theoretical basis for clinical application.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed as chronic ocular GVHD
  • Did not receive eye local immunosuppressive therapy
  • Non pregnant patients

Exclusion criteria

  • Have a history of eye surgery in the past six months
  • Suffering from other eye diseases (autoimmune diseases, glaucoma, serious infection, retinopathy, allergy, cataract, eye trauma, etc.)
  • Hormones or immunosuppressants were used before enrollment

Treatment and study plan

cyclosporine

Drug

The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months

Other names: CsA

Tacrolimus

Drug

The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months

Other names: FK506

Primary outcomes

  1. visual acuity

    Time frame: Within 4 hours of initial enrollment

    visual acuity

  2. visual acuity

    Time frame: At the first month of enrollment

    visual acuity

  3. visual acuity

    Time frame: At the third month of enrollment

    visual acuity

  4. visual acuity

    Time frame: At the sixth month of enrollment

    visual acuity

  5. Intraocular pressure

    Time frame: Within 4 hours of initial enrollment

    Intraocular pressure

  6. Intraocular pressure

    Time frame: At the first month of enrollment

    Intraocular pressure

  7. Intraocular pressure

    Time frame: At the third month of enrollment

    Intraocular pressure

  8. Intraocular pressure

    Time frame: At the sixth month of enrollment

    Intraocular pressure

  9. Ocular Surface Disease Index

    Time frame: Within 4 hours of initial enrollment

    Ocular Surface Disease Index

  10. Ocular Surface Disease Index

    Time frame: At the first month of enrollment

    Ocular Surface Disease Index

  11. Ocular Surface Disease Index

    Time frame: At the third month of enrollment

    Ocular Surface Disease Index

  12. Ocular Surface Disease Index

    Time frame: At the sixth month of enrollment

    Ocular Surface Disease Index

  13. Corneal fluorescein staining

    Time frame: Within 4 hours of initial enrollment

    Corneal fluorescein staining

  14. Corneal fluorescein staining

    Time frame: At the first month of enrollment

    Corneal fluorescein staining

  15. Corneal fluorescein staining

    Time frame: At the third month of enrollment

    Corneal fluorescein staining

  16. Corneal fluorescein staining

    Time frame: At the sixth month of enrollment

    Corneal fluorescein staining

  17. Tear break-up time

    Time frame: Within 4 hours of initial enrollment

    Tear break-up time

  18. Tear break-up time

    Time frame: At the first month of enrollment

    Tear break-up time

  19. Tear break-up time

    Time frame: At the third month of enrollment

    Tear break-up time

  20. Tear break-up time

    Time frame: At the sixth month of enrollment

    Tear break-up time

Sponsors and collaborators

Lead sponsor

Peking University Third Hospital

Other

Registry information

Official study title

Evaluation of Efficacy, Safety and Tolerability of 0.05% Cyclosporine and 0.1% Tacrolimus Eye Drops in the Treatment of Chronic Ocular Graft-versus-host Disease

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Mar 24, 2022
Registry last updated
Mar 24, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.